Workboat Indexes

Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Workboat Indexes
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zura Bio Limited - Class A Ordinary shares (NQ: ZURA )

3.160 -0.440 (-12.22%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Zura Bio Limited - Class A Ordinary shares

< Previous 1 2 Next >
Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis
From Zura Bio Limited
Via Business Wire
Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
From Zura Bio Limited
Via Business Wire
Zura Bio to Participate in Two Upcoming Investor Conferences in November
From Zura Bio
Via Business Wire
Zura Bio to Present at Three Upcoming Investor Conferences in September
From Zura Bio Limited
Via Business Wire
Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Zura Bio Limited
Via Business Wire
Zura Bio Completes Exchange Offer and Consent Solicitation and Notice to Exercise Right to Exchange Remaining Outstanding Warrants
From Zura Bio Limited
Via Business Wire
Zura Bio Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to its Warrants
From Zura Bio Limited
Via Business Wire
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
From Sagimet Biosciences Inc.
Via GlobeNewswire
Zura Bio Commences Warrant Exchange Offer and Consent Solicitation
From Zura Bio Limited
Via Business Wire
Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024
From Zura Bio Limited
Via Business Wire
Zura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and Immunology
From Zura Bio Limited
Via Business Wire
Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024
From Zura Bio Limited
Via Business Wire
Zura Bio Announces Participation in June Investor Conferences
From Zura Bio Limited
Via Business Wire
Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
From Zura Bio Limited
Via Business Wire
Zura Bio Announces Oversubscribed $112.5 Million Private Placement
From Zura Bio
Via Business Wire
Zura Bio Announces Robert Lisicki as CEO and Director
From Zura Bio Limited
Via Business Wire
Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer
From Zura Bio Limited
Via Business Wire
Zura Bio Announces Participation at March Conferences
From Zura Bio Limited
Via Business Wire
Zura Bio Announces Participation at February Investor Conferences
From Zura Bio Limited
Via Business Wire
Zura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMO
From Zura Bio Limited
Via Business Wire
Zura Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Dermatology Summit
From Zura Bio Limited
Via Business Wire
Zura Bio Announces Two Immunology Abstracts Presented at the World Allergy Congress in Bangkok
From Zura Bio Limited
Via Business Wire
Zura Bio Appoints Arnout Ploos van Amstel to its Board of Directors
From Zura Bio Limited
Via Business Wire
Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights
From Zura Bio Limited
Via Business Wire
Zura Bio Enters into Sponsored Research Agreement with Benaroya Research Institute
From Zura Bio Limited
Via Business Wire
Zura Bio Reports Second Quarter 2023 Financial Results and Recent Business Highlights
From Zura Bio Limited
Via Business Wire
Zura Bio to Join the Russell 2000® and Russell 3000® Indexes
From Zura Bio Limited
Via Business Wire
Zura Bio Completes Approximately $80 Million Financing with the Focus on Advancing ZB-106, a Potential First-in-class Anti-IL-17 and Anti-BAFF Dual Antagonist
From Zura Bio
Via Business Wire
Zura Bio Announces $80 Million Financing and the Licensing of Tibulizumab (ZB-106), a Potential First-in-Class anti-IL-17 and anti-BAFF Dual Antagonist for Autoimmune Diseases
From Zura Bio Limited
Via Business Wire
Zura Bio Announces Appointment of Chief Scientific Officer
From Zura Bio Limited
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Diversified Communications
© 2024 Diversified Communications. All rights reserved.